Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE "HPS2-THRIVE"


Phase 3 Results

Summary of Purpose

The primary aim is to assess the effects of raising HDL cholesterol (the good type) with extended release niacin/laropiprant 2g (previously known as MK−0524A) versus matching placebo on the risk of heart attack or coronary death, stroke, or the need for arterial bypass procedures (revascularisation) in people with a history of circulatory problems. The secondary aim is to assess the effects of extended release...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 27 January 2014.

1 Jan 2007 17 Apr 2007 1 Oct 2012 1 Oct 2012 1 Jan 2014 12 Jul 2013
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Prevention
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment


  • Martin Landray Phone: +44 1865 743743 Email: